Skip to main content
. 2019 Aug 23;19:712. doi: 10.1186/s12879-019-4315-6

Fig. 3.

Fig. 3

Cured prevalence by age group and multimorbidity (> = 2 conditions) among participants treated with DAA in the TOHVHP HCV cohort (n = 563)